Current State of ERG as Biomarker in Prostatic Adenocarcinoma.

dc.contributor.author	Ács, Balázs
dc.contributor.author	Szarvas, Tibor
dc.contributor.author	Szekely N
dc.contributor.author	Nyirády, Péter
dc.contributor.author	Szász, Attila Marcell
dc.date.accessioned	2016-08-09T18:50:29Z
dc.date.available	2016-08-09T18:50:29Z
dc.date.issued	2015
dc.identifier.citation	pagination=643-651; journalVolume=15; journalIssueNumber=8; journalTitle=CURRENT CANCER DRUG TARGETS;
dc.identifier.uri	http://repo.lib.semmelweis.hu//handle/123456789/2272
dc.description.abstract	In this review we briefly discuss the possible biomarkers of prostate cancer among them we focus and analyze the relevance of TMPRSS2-ERG fusion gene in line with ERG expression in the diagnosis of prostate cancer. Starting at diagnosis and genetic alterations in prostate carcinomas, we examine the incidence and detection of the most common genetic aberration in this tumor and its protein product as well. We also examined the correlation of clinicopathological factors and prognosis with ERG and the TMPRSS2-ERG fusion oncogene and ERG expression as predictive markers.
dc.relation.ispartof	urn:issn:1568-0096
dc.title	Current State of ERG as Biomarker in Prostatic Adenocarcinoma.
dc.type	Journal Article
dc.date.updated	2015-11-05T09:59:28Z
dc.language.rfc3066	en
dc.identifier.mtmt	2963888
dc.identifier.pubmed	26452381
dc.contributor.department	SE/AOK/I/II. Sz. Patológiai Intézet
dc.contributor.department	SE/AOK/K/Urológiai Klinika
dc.contributor.institution	Semmelweis Egyetem